-
ASCO 2021: Summary Overview and Outlook 1
Time of Update: 2021-06-10
The scope of clinical research including various indications and treatment settings, Metz Medicine will do some overview for your reference~The annual meeting of the American Society of Clinical Oncology ( ASCO ) will be held from June 4 to 8, 2021.
-
Regent Bio announced the interim results of its phase 1 clinical study of the CD137/4-1BB agonist antibody LVGN6051 at the 2021 ASCO annual meeting
Time of Update: 2021-06-10
Abstract number 2521 title Early safety and efficacy from a phase I open-label clinical trial of CD137 (4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab Report session Developmental Therapeutics-Immunotherapy report time June 4, 2021, 9 a.
-
ASCO 2021: Rongchang Bio-ADC's new drug Vidicuzumab once again appeared at the conference, showing blockbuster clinical data!
Time of Update: 2021-06-10
(Wallpaper#4534)Also led by Professor Guo Jun from Peking University Cancer Hospital and Professor Sheng Xinan in charge of vedicitumumab combined with PD-1 antibody teriprizumab for the preliminary Ib/II phase study of locally advanced or metastatic urothelial carcinoma The results were also reported for the first time at the meeting.
-
J Thorac Oncol: The impact of low-dose CT (LDCT) screening for primary lung cancer on the risk of subsequent brain metastasis (BM).
Time of Update: 2021-06-10
Based on large-scale population studies, low-dose CT (LDCT) screening for early detection of primary lung cancer (PLC) can reduce the risk of brain metastasis (BM) after the diagnosis of PLC.
-
ASCO 2021: Non-Small Cell Lung Cancer Special Session-Oral Report (02)
Time of Update: 2021-06-10
We evaluated the detection rate of ALK, BRAF, EGFR, ROS1 and PD-L1; use a complete next-generation sequencing panel (NGS); time from mNSCLC diagnosis (dx) to 1L treatment; TAT from biomarker order to result ; And the time from mNSCLCdx to the test result.
-
JNCI: Is immunotherapy for patients with metastatic NSCLC necessarily better than chemotherapy?
Time of Update: 2021-06-10
references:Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
-
Br J Cancer: Deubiquitinating enzyme USP9X: A potential therapeutic target for oral cancer
Time of Update: 2021-06-10
Further studies have shown that elevated expression levels of USP9X and MCL-1 correspond to the poor prognosis of OSCC patients.
The increased expression levels of USP9X and MCL-1 correspond to the poor prognosis of OSCC patients.
-
JCO: Comparison of the efficacy of two adjuvant treatments for patients with stage I HER2+ breast cancer
Time of Update: 2021-06-10
For patients with HER2-positive stage I breast cancer, compared with paclitaxel combined with trastuzumab therapy, adjuvant T-DM1 treatment for one year can obtain an excellent 3-year non-invasive disease survival rate without increasing clinically relevant toxic events Incidence rate.
-
ASCO 2021: New progress in immunotherapy!
Time of Update: 2021-06-10
On June 4, 2021, the annual event of the global oncology community-the American Society of Clinical Oncology ( ASCO ) annual meeting officially kicked off. BeiGene announced its expertise in the fiel
-
Nature: NK cells make tumors dormant
Time of Update: 2021-06-08
Before the metastasis begins to grow, cancer cells may have metastasized from the primary tumor to other sites (a process called metastasis), where they can stay dormant for a long time.
-
Nature: Intestinal cancer stem cells have adverse effects on neighboring cells
Time of Update: 2021-06-08
This allowed the authors to track intestinal stem cells expressing mutations in two key genes related to cancer, Kras and Pik3ca, and evaluate their wild-type neighboring cells.
presented evidence that revealed how stem cells carrying cancer-promoting mutations in the intestine affect.
-
Nat Commun: Heavy!
Time of Update: 2021-06-08
Recently, in a research report titled "Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy" published in the international journal Nature Communications , scientists from Georgia State University and other institutions found that a New types of macrophage-based immunotherapy may be effective in treating a range of cancers, including cancer types in advanced stages.
-
Nat Aging: Targeting the epigenetic enzyme KDM4 to help treat aging and tumors
Time of Update: 2021-06-08
In conclusion, the study uses KDM4 as the target and proposes a new therapeutic approach to manipulate cellular senescence and limit its contribution to age-related diseases including cancer .
With KDM4 as the target, a new therapeutic approach is proposed to manipulate cell senescence and limit its contribution to age-related diseases including cancer.
-
Broad Pharmaceuticals completed the first patient administration of two global innovative drugs and was approved by Australia I...
Time of Update: 2021-06-08
On June 2, Broad Pharmaceuticals announced that Telix Pharmaceuticals Limited (ASX: TLX), a global innovative radionuclide conjugated drug for prostate cancer imaging, TLX591-CDx, the group’s partner in the field of radionuclide conjugated drugs (RDC) (Illuccix®, 68Ga-HBED-CC-PSMA11) A clinical study in Japan recently completed the first patient administration; the radionuclide conjugate drug TLX591 (177Lu-DOTA-Rosopatamab) for the treatment of prostate cancer was approved for phase III The clinical research was approved by the Human Research Ethics Committee (Human Research Ethics Committee).
-
BCMAxCD3 bispecific antibody!
Time of Update: 2021-06-08
S. Food and Drug Administration ( FDA ) has granted a universal T cell redirection BCMxCD3 bispecific antibody teclistamab (JNJ-64007957, JNJ-7957) for the treatment of relapsed or refractory Breakthrough Drug Qualification (BTD) for multiple myeloma (MM).
-
Monthly inventory: May FDA&NMPA was approved for priority review of new drug CDE...
Time of Update: 2021-06-08
5，FDA7：4，Empaveli （pegcetacoplan）,Pylarify （plflufolastatF 18），FGFR2（CCA）Truseltiq （infigratinib），KRAS G12CLumakras （sotorasib）；2，Zynrelef （+），Myfembree （relugolix ++）；1，EGFR20NSCLCRybrevant （amivant
-
Liver Cancer: Efficacy and safety of Cabozantinib in the treatment of advanced liver cancer: from an international multi-center real world study
Time of Update: 2021-06-08
Therefore, research teams from Australia, Switzerland, and Germany conducted a real-world retrospective study to evaluate the efficacy and safety of cabozantinib in the treatment of advanced liver cancer.
-
Sci Rep: New artificial intelligence technology may be expected to detect cancerous tissues in patients in real time
Time of Update: 2021-06-08
Recently, in a research report titled "Digital dynamic discrimination of primary colorectal cancer using systemic indocyanine green with near-infrared endoscopy" published in the international journal Scientific Reports , scientists from the University of Dublin and other institutions developed a New surgical technology, which can use artificial intelligence technology to detect cancerous tissue in real time during surgery, which may fundamentally improve the treatment outcome of patients.
-
ASCO 2021: Summary Overview and Outlook 21 Overview of the latest breast cancer research (HER2-positive breast cancer column)
Time of Update: 2021-06-08
The prognostic performance of PREDICT+ in HER2-positive (HER2+) early breast cancer (EBC) patients (pts)PREDICT+ is a widely used free online tool, based on traditional clinicopathological characteristics, including HER2, developed to predict the individual mortality of EBC patients and assist clinical decision-making for treatment.
-
BCMA CAR-T cell therapy! Johnson & Johnson/Nanjing Legend cilta-cel in the treatment of relapsed/refractory multiple myeloma: the objective remission rate is as high as 98%!
Time of Update: 2021-06-08
BCMA-guided CAR-T cell therapy ciltacabtagene autoleucel The latest results from the 1b/2 CARTITUDE-1 study (n=97; NCT03548207) showed that after a median of 18 months of long-term follow-up, the objective response rate (ORR) reached 98%, and 80% of patients achieved strict complete remission.
